Treatment of psoriasis - new small molecules

Treatment of psoriasis - new small molecules.
This is a modified version of my invited lecture at the EADV Virtual Congress in 2020.
Currently, the only new molecule approved for psoriasis is apremilast.
This presentation focuses on drugs with are under development, including
JAK inhibitors, such as tofacitinib (trade names Xeljanz/Jakvinus) against JAK3 and 1 approved for psoriatic arthritis and rheumatoid arthritis; ruxolitinib (trade names Jakafi/Jakavi) against JAK1/JAK2 approved for hematological diseases and baricitinib (trade name Olumiant) against JAK1/JAK2, approved for rheumatoid arthritis.
Other new small molecules, such as PDE4 inhibitors and Bruton kinase inhibitors are currenly inverstigated.
#NotJustHairDiseases #ProfLidiaRudnicka

Видео Treatment of psoriasis - new small molecules канала prof. Lidia Rudnicka